Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1988 Sep;32(9):1400–1403. doi: 10.1128/aac.32.9.1400

In vivo activity of amikacin alone or in combination with clofazimine or rifabutin or both against acute experimental Mycobacterium avium complex infections in beige mice.

P R Gangadharam 1, V K Perumal 1, N R Podapati 1, L Kesavalu 1, M D Iseman 1
PMCID: PMC175876  PMID: 2848444

Abstract

The in vivo activity of amikacin, used alone or in combination with rifabutin or clofazimine or both, was assessed in the treatment of early and established Mycobacterium avium complex infections in beige mice. Amikacin given alone at a dose of 50 mg/kg, in one, two, or three divided doses, showed remarkable activity. Addition of clofazimine increased the activity significantly, but addition of the third drug, rifabutin, did not further improve the results. Amikacin-containing regimens are worthy of consideration for investigations in patients with M. avium complex infections.

Full text

PDF
1400

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bertram M. A., Inderlied C. B., Yadegar S., Kolanoski P., Yamada J. K., Young L. S. Confirmation of the beige mouse model for study of disseminated infection with Mycobacterium avium complex. J Infect Dis. 1986 Jul;154(1):194–195. doi: 10.1093/infdis/154.1.194. [DOI] [PubMed] [Google Scholar]
  2. Gangadharam P. R., Edwards C. K., 3rd Release of superoxide anion from resident and activated mouse peritoneal macrophages infected with Mycobacterium intracellulare. Am Rev Respir Dis. 1984 Nov;130(5):834–838. doi: 10.1164/arrd.1984.130.5.834. [DOI] [PubMed] [Google Scholar]
  3. Gangadharam P. R., Kesavalu L., Rao P. N., Perumal V. K., Iseman M. D. Activity of amikacin against Mycobacterium avium complex under simulated in vivo conditions. Antimicrob Agents Chemother. 1988 Jun;32(6):886–889. doi: 10.1128/aac.32.6.886. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Gangadharam P. R., Perumal V. K., Jairam B. T., Rao P. N., Nguyen A. K., Farhi D. C., Iseman M. D. Activity of rifabutin alone or in combination with clofazimine or ethambutol or both against acute and chronic experimental Mycobacterium intracellulare infections. Am Rev Respir Dis. 1987 Aug;136(2):329–333. doi: 10.1164/ajrccm/136.2.329. [DOI] [PubMed] [Google Scholar]
  5. Gangadharam P. R., Pratt P. F. In vitro response of murine alveolar and peritoneal macrophages to Mycobacterium intracellulare. Am Rev Respir Dis. 1983 Dec;128(6):1044–1047. doi: 10.1164/arrd.1983.128.6.1044. [DOI] [PubMed] [Google Scholar]
  6. Heifets L. B., Iseman M. D., Lindholm-Levy P. J. Determination of MICs of conventional and experimental drugs in liquid medium by the radiometric method against Mycobacterium avium complex. Drugs Exp Clin Res. 1987;13(9):529–538. [PubMed] [Google Scholar]
  7. Young L. S., Inderlied C. B., Berlin O. G., Gottlieb M. S. Mycobacterial infections in AIDS patients, with an emphasis on the Mycobacterium avium complex. Rev Infect Dis. 1986 Nov-Dec;8(6):1024–1033. doi: 10.1093/clinids/8.6.1024. [DOI] [PubMed] [Google Scholar]
  8. Young L. S. Management of opportunistic infections complicating the acquired immunodeficiency syndrome. Med Clin North Am. 1986 May;70(3):677–692. doi: 10.1016/s0025-7125(16)30946-4. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES